62 results
6-K
EX-99.1
PPBT
Purple Biotech Ltd
4 Jun 24
Report of Foreign Private Issuer
4:00pm
strategy (5T4 + ) | 31
Corporate highlights Purple Biotech (NASDAQ/TASE: PPBT) As of March 31, 2024 ADS Outstanding: 26.6 M Cash Balance: $10.8 M … signaling pathway has emerged as a promising therapeutic strategy for numerous cancers NT219 demonstrates a durable and dose - dependent suppression of STAT3
6-K
EX-99.1
PPBT
Purple Biotech Ltd
2 May 24
Report of Foreign Private Issuer
4:13pm
Opportunity of patient stratification strategy ( 5 T 4 + )
| 28 Corporate Highlights Purple Biotech (NASDAQ/TASE: PPBT) As of December 31 , 2023 ADS … the STAT 3 signaling pathway has emerged as a promising therapeutic strategy for numerous cancers NT 219 demonstrates a durable and dose - dependent
6-K
EX-99.1
PPBT
Purple Biotech Ltd
6 Mar 24
Report of Foreign Private Issuer
4:06pm
/ajcr0074519 5T4 is a Tumor Associated Antigen prevalent to several large indications Opportunity of patient stratification strategy (5T4 + ) | 26
Corpo … as a promising therapeutic strategy for numerous cancers NT219 demonstrates a durable and dose - dependent suppression of STAT3 tyrosine phosphorylation
6-K
EX-99.1
PPBT
Purple Biotech Ltd
21 Nov 23
Report of Foreign Private Issuer
4:00pm
is a Tumor Associated Antigen prevalent to several large indications Opportunity of patient stratification strategy (5T4 + ) | 24
Promising Proof o f … emerged as a promising therapeutic strategy for numerous cancers NT219 demonstrates a durable and dose - dependent suppression of STAT3 tyrosine
424B3
9keax0di
14 Nov 23
Prospectus supplement
4:13pm
F-1/A
ux3lmgu6rz8axt3wggt
13 Nov 23
Registration statement (foreign) (amended)
4:11pm
6-K
EX-99.1
fumfeb4rd415
2 Nov 23
Purple Biotech Fortifies NT219 Patent Protection
7:04am
F-1
w7543owq ejshrml850
30 Oct 23
Registration statement (foreign)
4:30pm
424B3
b8l7z4x
19 Oct 23
Prospectus supplement
4:40pm
6-K
EX-99.1
zeeddgs
13 Oct 23
Report of Foreign Private Issuer
7:09am
6-K
EX-99.1
ib30xs e4g5q
13 Sep 23
Report of Foreign Private Issuer
8:39am
6-K
EX-99.1
r2yt9
1 May 23
Notice of Annual General Meeting of Shareholders
4:00pm
6-K
EX-99.1
d1nop080s9nlr
19 Apr 23
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
8:17am
6-K
EX-99.1
idw3 ytxj5w7n6k2u
9 Nov 22
Report of Foreign Private Issuer
4:11pm
6-K
EX-99.1
3o6b4qlllrmv1iy2
2 Nov 22
Purple Biotech Appoints Lior Fhima as Chief Financial Officer
7:39am
6-K
EX-99.2
ht6pubpnjzdxyx6
4 Aug 22
Purple Biotech Reports Second Quarter 2022 Financial Results
7:31am
6-K
EX-99.1
r7pmo
18 Jul 22
Notice of Annual General Meeting of Shareholders
4:25pm
6-K
EX-99.1
dtj8c mfo3fvlm7gsm
6 Jun 22
Report of Foreign Private Issuer
7:33am